All In Biotech

Drug Trial Radar · NCT07906093

Expanded Access Program to Provide STC-15 to Patients With Selected Advanced Cancer

Expanded Access Program to Provide STC-15 to Adult and Adolescent Patients With Selected Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
STORM Therapeutics LTDIndustry
Sponsor type
Industry
Collaborators
Impatients N.V. trading as myTomorrows
First posted
Oct 30, 2026

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 12 years

Summary

As written by the sponsor on the registry.

This Expanded Access Program (EAP) is intended to provide access to STC-15 outside of a clinical study setting for adult and adolescent patients with serious or life-threatening malignancies who, in the opinion of their treating physician, may benefit from treatment with STC-15, have no satisfactory alternative therapeutic options available, are not eligible for or cannot reasonably access an ongoing STC-15 clinical trial within a clinically appropriate timeframe, and meet the eligibility criteria described in this protocol.

Conditions

  • Cancer

Interventions

  • STC-15Drug

    STC-15 will be administered orally to adults three times a week in continuous 21-day cycles. Pediatric dosing will be individualized based on age, weight/BSA, organ function, formulation/administration feasibility, and available clinical pharmacology data, and requires Sponsor medical approval.

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.